Aratana Therapeutics : Appoints Chief Operating Officer

LEAWOOD, Kan., June 29, 2016/PRNewswire / -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced today that the Company has appointed Brent A. StandridgeChief Operating Officer, a new position within Aratana.

'As Aratana prepares to launch its recently approved products, this new executive role emphasizes the company's commitment to sales operations and distribution,' explains Steven St. Peter, M.D., President and Chief Executive Officer of Aratana. 'Through Brent's experience in managing a large animal health business of $500 millionand a staff of more than 300, we expect he will lead us in successfully launching and selling our innovative therapeutics.'

Brent A. Standridge
Mr. Standridge has decades of experience in U.S. and Canadian animal health markets. Most recently, he consulted for the generic veterinary medicine maker Putney, Inc., which was acquired by Dechra Pharmaceuticals PLC in March 2016. Previously, Mr. Standridge spent 28 years with Wyeth's animal health division, Fort Dodge Animal Health, which consisted of 11 years as Senior Vice President of Sales and Marketing of North Americawhere he was responsible for all sales and marketing activities.

While with Fort Dodge Animal Health, Mr. Standridge successfully integrated staff, products and services from animal health company acquisitions of Bristol Myers, Parke-Davis, AH Robins, American Cyanamid, Syntex Animal Health and Solvay Animal Health. He also played an integral role during the acquisition of Wyeth by Pfizer in October 2009. Under his leadership, his team earned Manufacturer of the Year Award and Best Overall Distributor Relations, among others. Mr. Standridge graduated from The Ohio State Universitywith a B.S. in Animal Science.

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The Company's pipeline includes therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.

Forward-Looking Statements Disclaimer
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements with respect to our ability to bring several innovative products to market; expectations regarding the hiring of a Chief Operating Officer; and the Company's plans and opportunities, including without limitation offering innovative therapeutics that fulfill serious unmet needs.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our history of operating losses and our expectation that we will continue to incur losses for the foreseeable future; failure to obtain sufficient capital to fund our operations; risks relating to the impairment of intangible assets AT-004, AT-005, AT-007 and AT-011; unstable market and economic conditions; restrictions on our financial flexibility due to the terms of our credit facility; our substantial dependence upon the success of our product candidates; development of our biologic product candidates is dependent upon relatively novel technologies and uncertain regulatory pathways, and biologics may not be commercially viable; denial or delay of regulatory approval for our existing or future product candidates; failure of our product candidates that receive regulatory approval to obtain market approval or achieve commercial success; failure to realize anticipated benefits of our acquisitions and difficulties associated with integrating the acquired businesses; development of pet therapeutics is a lengthy and expensive process with an uncertain outcome; competition in the pet therapeutics market, including from generic alternatives to our product candidates, and failure to compete effectively; failure to identify, license or acquire, develop and commercialize additional product candidates; failure to attract and retain senior management and key scientific personnel; our reliance on third-party manufacturers, suppliers and partners; regulatory restrictions on the marketing of our product candidates; our small commercial sales organization, and any failure to create a sales force or collaborate with third-parties to commercialize our product candidates; difficulties in managing the growth of our company; significant costs of being a public company; risks related to the restatement of our financial statements for the year ended December 31, 2013, and the identification of a material weakness in our internal control over financial reporting; changes in distribution channels for pet therapeutics; consolidation of our veterinarian customers; limitations on our ability to use our net operating loss carryforwards; impacts of generic products; safety or efficacy concerns with respect to our product candidates; effects of system failures or security breaches; failure to obtain ownership of issued patents covering our product candidates or failure to prosecute or enforce licensed patents; failure to comply with our obligations under our license agreements; effects of patent or other intellectual property lawsuits; failure to protect our intellectual property; changing patent laws and regulations; non-compliance with any legal or regulatory requirements; litigation resulting from the misuse of our confidential information; the uncertainty of the regulatory approval process and the costs associated with government regulation of our product candidates; failure to obtain regulatory approvals in foreign jurisdictions; effects of legislative or regulatory reform with respect to pet therapeutics; the volatility of the price of our common stock; our status as an emerging growth company, which could make our common stock less attractive to investors; dilution of our common stock as a result of future financings; the influence of certain significant stockholders over our business; and provisions in our charter documents and under Delawarelaw could delay or prevent a change in control. These and other important factors discussed under the caption 'Risk Factors' in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 15, 2016, along with our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Contacts
For investor inquires:
Craig Tooman
ctooman@aratana.com
(913) 353-1026

For media inquiries:
Rachel Reiff
rreiff@aratana.com
(913) 353-1050

Logo - http://photos.prnewswire.com/prnh/20160425/359503LOGO

SOURCE Aratana Therapeutics, Inc.